# BlackThorn Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blackthorn-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.blackthornrx.com
- Total disclosed funding: $130M
- Latest round: Series B (Jun 13, 2019)
- Investors on record: 11

## About

BlackThorn Therapeutics, Inc. is a biopharmaceutical company focusing on developing innovative therapies for neurological and psychiatric disorders, leveraging advanced technologies and data-driven approaches to address unmet medical needs.Founded in 2013 and headquartered in San Francisco, US, BlackThorn Therapeutics, Inc. specializes in the development of therapeutic solutions for neurological and psychiatric conditions. The company has received a total of three funding deals, with the most recent being a Series B round in June 2019, raising USD 76.00 mn from a group of investors including Polaris Partners and Johnson & Johnson Innovation. The total amount raised by the company to date is USD 76.00 mn, with a current valuation of USD 168.57 mn.BlackThorn Therapeutics develops targeted therapies designed to treat various neurological and psychiatric disorders. Their product pipeline includes novel drug candidates aimed at improving patient outcomes through precision medicine, focusing on the molecular mechanisms underlying these conditions.The company's revenue model primarily involves funding from investment rounds, with the latest round generating USD 76.00 mn. This funding supports their operations and product development, providing the necessary capital to advance their therapeutic candidates towards clinical trials and market entry.With the USD 76.00 mn raised in their most recent Series B funding round in June 2019, BlackThorn Therapeutics plans to expand its research and development efforts, particularly focusing on launching new therapeutic candidates in the coming years. The company aims to penetrate new geographical markets, particularly targeting Europe and parts of Asia by 2025, to broaden their impact and reach within the mental health space. Recent funding will be utilized to enhance their research capabilities and expedite the clinical development of their lead candidates.

## Funding rounds

- Series B, Jun 13, 2019, $76M — ARCH Venture Partners, Polaris Partners, Alexandria Venture Investments, Johnson & Johnson Innovation, Altitude Life Science Ventures, Mercury, GV, Premier Partners, Biomatics Capital Partners, Vertex Ventures HC, Scripps Center for Mass Spectrometry and Metabolomics
- Series A, Dec 19, 2016, $14M — GV, Biomatics Capital Partners
- Series A, Dec 16, 2016, $40M — ARCH Venture Partners, Alexandria Venture Investments, Johnson & Johnson Innovation, Altitude Life Science Ventures, Mercury

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series A, Series B
- Mercury (https://capitalatlas.ai/funds/mercury) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series B
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series B
- Scripps Center for Mass Spectrometry and Metabolomics — Series B